The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.